ACCCBUZZ BLOG

During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.

In recognition of Bladder Health Awareness Month, ACCC shares the results of a recent quality improvement study, which provides impactful steps cancer centers can take to mitigate disparities in bladder cancer.

ACCC is excited to share its new provider resources for TIL cell therapy, including a referral readiness checklist, patient pathway guide, and white paper with tangible steps for improving access.

Advanced practice providers (APPs) are essential members of the cancer care team with roles that vary depending on institutional policies and state regulations. Empowering APPs to work at the top of their scope leads to stronger care delivery.

While ADCs have emerged as a promising development for patients with NSCLC, they present unique challenges in clinical practice, such as optimal patient selection, treatment sequencing, and toxicity management. ADCs can also elicit significant adverse events, particularly when combined with immunotherapy, raising concerns about overlapping toxicities and the need for close monitoring for treatment-related complications.

Genetic testing and molecular profiling can be the key to better outcomes for patients with pancreatic cancer by allowing oncologists to implement more targeted therapies.

ACCC is committed to helping cancer care team members, patients, and caregivers understand how bispecific antibody treatments fit within the cancer care continuum, how they differ from CAR T-cell therapy, and the education and resources available to patients and their families.

The first facility on Long Island, NY to offer next-generation sequencing with point-of-care genomic testing opened this May, and brought access to state of the art medical technology to patients in 6 different counties in the region.

Explore the role of cardio-oncology in understanding and managing potential cardiovascular complications of immune checkpoint inhibitors.

ACCCBuzz recognizes June as Cancer Immunotherapy Month.

Explore insights from this LinkedIn Live event highlighting the crucial role of pathologists within the multidisciplinary cancer care team.

ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.

Highlights from a LUNGevity Lung Cancer Precision Medicine Summit that addressed critical issues surrounding biomarker testing in non-small cell lung cancer.

LUNGevity invited ACCC and other stakeholders across the oncology world to Washington DC, for their second Health Equity Summit on Tuesday, March 12.

ACCC, ACS CAN, and LUNGevity, launched a series of focus groups earlier this year aimed at making the case for increasing access to comprehensive genomic profiling for Medicaid beneficiaries.

ACCC has developed an initiative to support health care providers in applying evidence-based treatment selection for patients with advanced/metastatic gastric cancer. Learn more.

At the ACCC 40th NOC, an exclusive EHR Working Summit was held to understand and explore effective practices/workaround solutions for streamlined biomarker test ordering and results management.

As CAR T-cell therapies provide new treatment options for patients with certain hematologic malignancies, it is important that more cancer centers and programs deliver them.

Key takeaways from day 1 of #ACCCNOC.

Through a series of education projects, ACCC is committed to providing the resources the multidisciplinary cancer care team will need to navigate the complex precision medicine landscape and deliver next generation cancer care.

As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.

In the era of personalized medicine, biomarker testing is a tool the oncology workforce can and should leverage to deliver next generation cancer care.